Bravadin - Instructions For Use, Indications, Doses

2024 Author: Rachel Wainwright | [email protected]. Last modified: 2023-12-15 07:39

Bravadin

Instructions for use:

1. 1. Release form and composition
2. 2. Indications for use
3. 3. Contraindications
4. 4. Method of application and dosage
5. 5. Side effects
6. 6. Special instructions
7. 7. Drug interactions
8. 8. Terms and conditions of storage

Prices in online pharmacies:

from 299 rub.

Buy

Bravadin is a drug of antiarrhythmic and antianginal action.

Release form and composition

Bravadin is available in the form of film-coated tablets:

• 5 mg tablets: biconvex, oval, pale orange, scored on one side; on the fracture of the tablet, the core is visible in the form of a rough white mass and a pale orange film shell (14 pcs. in blisters, in a cardboard box 1, 2, 4, 6 or 7 packages; 15 pcs. in blisters, in a cardboard box 2, 4 or 6 packages);
• 7.5 mg tablets: slightly biconvex, round, pale orange, beveled; on the fracture of the tablet, the core is visible in the form of a rough white mass and a pale orange film shell (14 pcs. in blisters, in a cardboard box 1, 2, 4, 6 or 7 packages; 15 pcs. in blisters, in a cardboard box 2, 4 or 6 packs).

Composition for 1 tablet:

• active substance: ivabradine (in the form of ivabradine hydrobromide) - 5 mg or 7.5 mg;
• auxiliary components: povidone, colloidal silicon dioxide, lactose monohydrate, magnesium stearate, microcrystalline cellulose, croscarmellose sodium;
• film sheath: Opadrai orange 03H32599 (titanium dioxide, propylene glycol, dye iron oxide red, hypromellose, talc, dye iron oxide yellow).

Indications for use

Bravadin is used in adult patients with normal sinus rhythm to treat stable angina pectoris. The drug is prescribed in case of intolerance to beta-blockers and in the presence of contraindications to their use, as well as in conjunction with beta-blockers, if adequate control of stable angina pectoris was not achieved against the background of the optimal dose of beta-blocker.

Bravadin is also used in patients with CHF (chronic heart failure), with sinus rhythm and heart rate (heart rate) of at least 70 beats per minute to reduce the risk of developing cardiovascular complications.

Contraindications

Absolute:

• acute myocardial infarction;
• sinoatrial blockade;
• unstable angina;
• cardiogenic shock;
• sick sinus syndrome;
• atrioventricular block III degree;
• bradycardia (before starting therapy, resting heart rate less than 60 beats per minute);
• acute or unstable heart failure;
• severe arterial hypotension;
• the presence of an artificial pacemaker operating in a constant stimulation mode;
• severe liver failure;
• lactose intolerance, glucose-galactose malabsorption, lactase deficiency;
• children and adolescents up to 18 years of age (since the safety and efficacy of the drug in children and adolescents have not been studied);
• During pregnancy and breastfeeding;
• simultaneous use with macrolide antibiotics (josamycin, clarithromycin, telithromycin, oral erythromycin), azole antifungals (itraconazole, ketoconazole), nefazodone and HIV protease inhibitors (ritonavir, nelfinavir);
• hypersensitivity to the main or auxiliary components of the drug.

Relative (Bravadin is used with caution):

• recent stroke;
• asymptomatic left ventricular dysfunction;
• arterial hypotension;
• congenital lengthening of the QT interval;
• atrioventricular block II degree;
• CHF (NYHA functional class IV);
• severe renal failure;
• moderate hepatic impairment;
• pigmentary retinal degeneration;
• simultaneous use with non-potassium-sparing diuretics;
• simultaneous use with drugs that prolong the QT interval;
• simultaneous use with diltiazem and verapamil;
• simultaneous use with grapefruit juice and moderate inducers and inhibitors of the CYP3A4 isoenzyme.

Method of administration and dosage

Bravadin tablets are taken orally with meals, twice a day (morning and evening).

With stable angina pectoris, the drug is prescribed in an initial daily dose of 10 mg (2 times a day, 5 mg). Depending on the obtained therapeutic effect, after 3-4 weeks of treatment, it is possible to increase the daily dose to 15 mg (2 times a day, 7.5 mg). If, during the period of treatment with the drug, the resting heart rate decreases to 50 beats per minute or less, or the patient develops symptoms associated with bradycardia (increased fatigue, dizziness, a marked decrease in blood pressure), the daily dose of Bravadin should be reduced to 5 mg (2 times day, 2.5 mg). If symptoms of severe bradycardia persist and a heart rate of less than 50 beats per minute, drug treatment should be discontinued.

With CHF, the initial daily dose is 10 mg (2 times a day, 5 mg). After 2 weeks, it is possible to increase the daily dose to 15 mg (2 times a day, 7.5 mg each), if the heart rate at rest is stable above 60 beats per minute. With a heart rate of less than 50 beats per minute or symptoms of bradycardia, it is necessary to reduce the dose to 2.5 mg (2 times a day, 1.25 mg). With a heart rate of 50-60 beats per minute, the daily dose of Bravadin is 10 mg (2 times a day, 5 mg). If symptoms of severe bradycardia and heart rate remain less than 50 beats per minute, drug treatment should be discontinued.

In patients with impaired renal function (creatinine clearance more than 15 ml / min), Bravadin is used in standard recommended doses.

In elderly patients (over 75 years old), treatment begins with a daily dose of 5 mg (2 times a day, 2.5 mg). In the future, the dose may be increased.

With mild hepatic insufficiency, dose adjustment is not required, with moderate liver failure, the drug is used with caution, with severe hepatic insufficiency, the use of Bravadin is contraindicated.

Side effects

• gastrointestinal tract: infrequently - diarrhea or constipation, nausea;
• respiratory system: infrequently - shortness of breath;
• cardiovascular system: often - bradycardia, ventricular premature beats, atrioventricular block I degree, uncontrolled blood pressure; infrequently - a marked decrease in blood pressure, supraventricular premature beats, palpitations; very rarely - atrioventricular block II and III degree, atrial fibrillation, sick sinus syndrome;
• nervous system: often - headache, dizziness; frequency unknown - syncope;
• sense organs: very often - photopsia (false light sensations); often - blurred vision; infrequently - vertigo;
• musculoskeletal system: infrequently - muscle spasms;
• skin and subcutaneous tissues: infrequently - skin rash, Quincke's edema; rarely - erythema, pruritus, urticaria;
• laboratory and instrumental parameters: infrequently - eosinophilia, lengthening of the QT interval, hyperuricemia, increased plasma creatinine concentration;
• general disorders: infrequently - increased fatigue, asthenia; rarely - malaise.

special instructions

Bravadin should not be used to treat or prevent arrhythmias, as in this case it is ineffective. When a tachyarrhythmia occurs, the effectiveness of the drug decreases. The use of Bravadin is also not recommended for atrial fibrillation or other types of arrhythmias associated with the function of the sinus node.

With the appearance of a feeling of palpitations, worsening of the course of angina pectoris and irregular heart rhythm, it is necessary to conduct clinical observation (including an ECG study) for the patient to detect paroxysmal or permanent atrial fibrillation.

In patients with CHF taking Bravadin, the risk of atrial fibrillation increases. Most often, atrial fibrillation occurs in individuals who simultaneously take class I antiarrhythmic drugs and amiodarone with ivabradine.

In patients with CHF, when changing antihypertensive therapy, it is necessary to regularly (at certain time intervals) monitor blood pressure.

During treatment with Bravadin, the ability to drive vehicles may deteriorate, which is associated with side effects from the organ of vision, namely photopsy. Particular care must be taken when driving a car or other machinery at night.

Drug interactions

Due to the high pharmacological activity and the significant likelihood of interaction of ivabradine with other drugs / substances, recommendations for the combined use of Bravadin and other drugs can only be given by the attending physician.

Terms and conditions of storage

Keep out of reach of children at a temperature not exceeding 25 ° C.

The shelf life is 3 years.

Bravadin: prices in online pharmacies

Drug name Price Pharmacy

Bravadin 7.5 mg film-coated tablets 28 pcs. 299 r Buy

Bravadin tablets p.p. 5mg 28 pcs. 421 r Buy

Bravadin 5 mg film-coated tablets 28 pcs. 421 r Buy

Bravadin tablets p.p. 7.5mg 28 pcs. 474 r Buy

Bravadin 5 mg film-coated tablets 56 pcs. 502 RUB Buy

Bravadin 7.5 mg film-coated tablets 56 pcs. RUB 631 Buy

Bravadin tablets p.p. 5mg 56 pcs. 644 r Buy

Bravadin tablets p.p. 7.5mg 56 pcs. 850 RUB Buy

See all offers from pharmacies

Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!